Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
Front Pharmacol
.
2020 Nov 30:11:621934.
doi: 10.3389/fphar.2020.621934.
eCollection 2020.
Authors
Lucia Gozzo
1
,
Laura Longo
1
,
Daniela Cristina Vitale
1
,
Filippo Drago
1
2
3
Affiliations
1
Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, Catania, Italy.
2
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
3
Centre for Research and Consultancy in HTA and Drug Regulatory Affairs, University of Catania, Catania, Italy.
PMID:
33329008
PMCID:
PMC7734326
DOI:
10.3389/fphar.2020.621934
No abstract available
Keywords:
COVID19; European Medicines Agency; dexamethasone; drug repurposing; off-label.